{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:41:43Z","timestamp":1792010503894,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018747","name":"SkylineDx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejca.2022.12.021","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T12:04:26Z","timestamp":1672401866000},"page":"155-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Identification of stage I\/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP)"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2516-5181","authenticated-orcid":false,"given":"Teresa","family":"Amaral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Sinnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eftychia","family":"Chatziioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Niessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8019-1577","authenticated-orcid":false,"given":"Ulrike","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Keim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6185-4945","authenticated-orcid":false,"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jvalini","family":"Dwarkasing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9licia","family":"Tjien-Fooh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7334-5905","authenticated-orcid":false,"given":"Renske","family":"Wever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Flatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1274-2613","authenticated-orcid":false,"given":"Stephan","family":"Forchhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.12.021_bib1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.12.021_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus ipilimumab in resected stage III or IV melanoma [Internet]","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.12.021_bib3","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.12.021_bib4","first-page":"1","article-title":"The new era of adjuvant therapies for melanoma [Internet]","author":"Eggermont","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2022.12.021_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.12.021_bib6","unstructured":"Nivolumab in treating Stage IIB\/C melanoma patients (CheckMate 76K). +https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04099251?term=checkmate+76&cond=melanoma&draw=2&rank=1."},{"key":"10.1016\/j.ejca.2022.12.021_bib7","unstructured":"NivoMela trial:adjuvant Nivolumab treatment in stage II (IIA, IIB, IIC) high-risk melanoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04309409 [Internet] Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04309409."},{"key":"10.1016\/j.ejca.2022.12.021_bib8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2016.10.018","article-title":"Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013 [Internet]","volume":"76","author":"Landow","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.ejca.2022.12.021_bib9","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/jid.2014.452","article-title":"More people die from thin melanomas (\u22641 mm) than from thick melanomas (>4 mm) in Queensland, Australia","volume":"135","author":"Whiteman","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2022.12.021_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.00202","article-title":"Prognosis of patients with primary melanoma stage I and II according to American Joint committee on cancer version 8 validated in two independent cohorts: implications for adjuvant treatment","author":"Garbe","year":"2022","journal-title":"JCO"},{"key":"10.1016\/j.ejca.2022.12.021_bib11","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2022.12.021_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2020.08.029","article-title":"Identification of stage I\/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model","volume":"140","author":"Eggermont","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.12.021_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14122854","article-title":"Using a clinicopathologic and gene expression (CP-GEP) model to identify stage I\u2013II melanoma patients at risk of disease relapse","volume":"14","author":"Mulder","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2022.12.021_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/PO.19.00206","article-title":"A model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma","author":"Bellomo","year":"2020","journal-title":"JCO Precis Oncol DOI"},{"key":"10.1016\/j.ejca.2022.12.021_bib15","article-title":"Trends in sentinel lymph node biopsy enactment for cutaneous melanoma","author":"El Sharouni","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2022.12.021_bib16","article-title":"Clinically significant risk thresholds in the management of primary cutaneous melanoma: a survey of melanoma experts [Internet]","author":"Bartlett","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2022.12.021_bib17","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-022-11884-8","article-title":"Why treatment risk thresholds are needed for patients with melanoma","author":"Bartlett","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2022.12.021_bib18","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-6534-z","article-title":"MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial","volume":"20","author":"Soliman","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2022.12.021_bib19","article-title":"Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer","author":"Mcveigh","year":"2017","journal-title":"targets Ther"},{"key":"10.1016\/j.ejca.2022.12.021_bib20","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2018-0912","article-title":"Guidance of sentinel lymph node biopsy decisions in patients with T1\u2013T2 melanoma using gene expression profiling","author":"Vetto","year":"2019","journal-title":"Futur Oncol"},{"key":"10.1016\/j.ejca.2022.12.021_bib21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","article-title":"Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma","volume":"21","author":"Gerami","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.12.021_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jncics\/pky032","article-title":"A prognostic gene signature expressed in primary cutaneous melanoma: synergism with conventional staging [Internet]","volume":"2","author":"Brunner","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.ejca.2022.12.021_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2019.10.027","article-title":"Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma","author":"Amaral","year":"2020","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922018329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922018329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:04Z","timestamp":1760733604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922018329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":23,"alternative-id":["S0959804922018329"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.12.021","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of stage I\/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}